Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S. Registration Trial, reported by in a first report...
Videos | Stents Bioresorbable | November 07, 2017
A discussion with Ajay Kirtane, M.D., SM, director of the cardiac catheterization laboratories at New York-Presbyterian...
Thirty-Day ABSORB IV Results Demonstrate Improvements Still Needed in Bioresorbable Stents
News | Stents Bioresorbable | October 31, 2017
October 31, 2017 – Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular...
FDA Investigating Increased Major Adverse Cardiac Event Rates of Absorb Bioresorbable Stent
News | Stents Bioresorbable | October 31, 2017
October 31, 2017 — The U.S. Food and Drug Administration (FDA) issued a warning to healthcare providers that interim...
Amaranth Medical to Share Bioresorbable Scaffold Data at TCT
News | Stents Bioresorbable | October 25, 2017
October 25, 2017 — Amaranth Medical will provide an update at the annual Transcatheter Cardiovascular Therapeutics (TCT...
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable | September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular...
Videos | Stents Bioresorbable | March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses the...
BVS, Absorb stent, bioresorbable scaffold, ABSORB III data, ABSORB III results
Feature | Stents Bioresorbable | March 21, 2017 | Dave Fornell
March 21, 2017 — In the late-breaking ABSORB III Trial two year results presented at the American College of Cardiology...
Blog | Stents | February 13, 2017
Stents were the key focus of interventional cardiology for more than 20 years, but the focus has changed in recent...
Blog | January 30, 2017
DAIC has worked hard to bring useful technology news and resources to our readers. While we conduct reader surveys and...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable | January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers...
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OCT...
Absorb, bioresorbable stent, BVS, top cardiology story of 2016

The FDA clearance of the first fully bioresorbable stent, the Abbott Absorb BVS, was by far the top story of 2016. Readers clearly had a massive interest in this technology based on their page views of this article, related bioresorbable stent content and a video interviews with key ABSORB study investigators.

Feature | December 21, 2016 | Dave Fornell
The Diagnostic and Interventional Cardiology (DAIC) website had a record year in 2016, breaking 1 million page views...
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin...
Videos | Stents Bioresorbable | November 09, 2016
Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research Foundation's...